Overview of Assets
Our Priority and Growth Potential Assets give investors access to life sciences businesses with unique exposure across diverse modalities, therapeutic areas and geographies.
Our assets are largely maturing clinical development or commercial companies, nearing significant value inflection or realisation points, in which we hold meaningful stakes.
4 Priority Assets
Our 4 Priority Assets are those which we believe will generate the most significant returns for Malin. We will focus our capital and operational resources on these assets.
Our strategic objective is to support value creation in the Priority Assets.
74%
Priority Assets
Dec-19 IPEV
fair value
breakdown
26%
Growth Potential Assets
4 Growth Potential Assets
We will continue to support the progression of these assets as they target important strategic, scientific and operational milestones.
Early-stage assets
Revenue generative assets
Latest investee company news
Stay up to date
Sign up to Malin news alerts so you never miss a key company update.